Humanigen is a biopharmaceutical company focused on developing its immuno-oncology and immunology portfolio of monoclonal antibodies. Co. is focusing on the development of its key product candidate, lenzilumab, its Humaneered® anti-human GM-CSF immunotherapy, through a clinical research agreement to study the effect of lenzilumab on the safety of Yescarta®, axicabtagene ciloleucel including cytokine release syndrome, and neurotoxicity. Co. is creates combinatory gene-edited CAR-T therapies to improve efficacy. Co. is also developing its own chimeric antigen receptor T-cell programs based on the backbone of ifabotuzumab and HGEN005, in unmet medical need and rare/orphan oncology conditions. The HGEN stock yearly return is shown above.
The yearly return on the HGEN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HGEN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|